News Allergan negotiates option to buy neurology biotech Allergan to co-develop Parkinson's drug with Lysosomal Therapeutics
News Biogen courts controversy with $750k-a-year rare disease dru... Biogen's SMA treatment approved - but price is $125,000 per dose
News Roche and AC Immune's Alzheimer's drug on right track Data suggest high dose used in phase 3 trial is most effective
News Angelini Pharma's R&D chief heads for the exit Dr Rafal Kaminski's near five-year tenure as chief scientific officer of Italy's Angelini Pharma will come to an end in the next couple of weeks.
Sales & Marketing Sponsored Securing your ROI: Turning post-acquisition integration into... Join Forinnovia and Little Cube Consulting for a webinar on securing post-acquisition ROI.